SymBio raises $24 mn to advance bendamustine and other pipeline projects
This article was originally published in Scrip
The Japanese venture SymBio Pharmaceuticals has raised ¥2.0 billion ($24 million) in a Series E financing led by two major existing investors, Cephalon and the Japanese private equity firm JAFCO.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.